AbbVie Announces Ukrainian Foray
News: US-based drugmaker AbbVie has announced a new foray into the Ukrainian market, reports Interfax-Ukraine. AbbVie's portfolio includes medicines that address some of the world's most serious diseases. The company has more than 20 new molecules in the final and intermediate stage of clinical trials. The company is also engaged in the development of drugs for the treatment of hepatitis C infection, rheumatoid arthritis, psoriasis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, spondyloarthropathy, multiple myeloma and endometriosis.